Motivation: Alternative splice site selection is inherently competitive and the probability of a given splice site to be used also depends on the strength of neighboring sites. Here, we present a new model named the competitive splice site model (COSSMO), which explicitly accounts for these competitive effects and predicts the percent selected index (PSI) distribution over any number of putative splice sites. We model an alternative splicing event as the choice of a 3' acceptor site conditional on a fixed upstream 5' donor site or the choice of a 5' donor site conditional on a fixed 3' acceptor site. We build four different architectures that use convolutional layers, communication layers, long short-term memory and residual networks, respectively, to learn relevant motifs from sequence alone. We also construct a new dataset from genome annotations and RNA-Seq read data that we use to train our model. Results: COSSMO is able to predict the most frequently used splice site with an accuracy of 70% on unseen test data, and achieve an R2 of 0.6 in modeling the PSI distribution. We visualize the motifs that COSSMO learns from sequence and show that COSSMO recognizes the consensus splice site sequences and many known splicing factors with high specificity. Availability and implementation: Model predictions, our training dataset, and code are available from http://cossmo.genes.toronto.edu. Supplementary information: Supplementary data are available at Bioinformatics online.

BACKGROUND: Tumour samples containing distinct sub-populations of cancer and normal cells present challenges in the development of reproducible biomarkers, as these biomarkers are based on bulk signals from mixed tumour profiles. ISOpure is the only mRNA computational purification method to date that does not require a paired tumour-normal sample, provides a personalized cancer profile for each patient, and has been tested on clinical data. Replacing mixed tumour profiles with ISOpure-preprocessed cancer profiles led to better prognostic gene signatures for lung and prostate cancer. RESULTS: To simplify the integration of ISOpure into standard R-based bioinformatics analysis pipelines, the algorithm has been implemented as an R package. The ISOpureR package performs analogously to the original code in estimating the fraction of cancer cells and the patient cancer mRNA abundance profile from tumour samples in four cancer datasets. CONCLUSIONS: The ISOpureR package estimates the fraction of cancer cells and personalized patient cancer mRNA abundance profile from a mixed tumour profile. This open-source R implementation enables integration into existing computational pipelines, as well as easy testing, modification and extension of the model.

MOTIVATION: Gene expression data are currently collected on a wide range of platforms. Differences between platforms make it challenging to combine and compare data collected on different platforms. We propose a new method of cross-platform normalization that uses topic models to summarize the expression patterns in each dataset before normalizing the topics learned from each dataset using per-gene multiplicative weights. RESULTS: This method allows for cross-platform normalization even when samples profiled on different platforms have systematic differences, allows the simultaneous normalization of data from an arbitrary number of platforms and, after suitable training, allows for online normalization of expression data collected individually or in small batches. In addition, our method outperforms existing state-of-the-art platform normalization tools. AVAILABILITY AND IMPLEMENTATION: MATLAB code is available at http://morrislab.med.utoronto.ca/plida/.

BACKGROUND: High-throughput sequencing allows the detection and quantification of frequencies of somatic single nucleotide variants (SNV) in heterogeneous tumor cell populations. In some cases, the evolutionary history and population frequency of the subclonal lineages of tumor cells present in the sample can be reconstructed from these SNV frequency measurements. But automated methods to do this reconstruction are not available and the conditions under which reconstruction is possible have not been described. RESULTS: We describe the conditions under which the evolutionary history can be uniquely reconstructed from SNV frequencies from single or multiple samples from the tumor population and we introduce a new statistical model, PhyloSub, that infers the phylogeny and genotype of the major subclonal lineages represented in the population of cancer cells. It uses a Bayesian nonparametric prior over trees that groups SNVs into major subclonal lineages and automatically estimates the number of lineages and their ancestry. We sample from the joint posterior distribution over trees to identify evolutionary histories and cell population frequencies that have the highest probability of generating the observed SNV frequency data. When multiple phylogenies are consistent with a given set of SNV frequencies, PhyloSub represents the uncertainty in the tumor phylogeny using a "partial order plot". Experiments on a simulated dataset and two real datasets comprising tumor samples from acute myeloid leukemia and chronic lymphocytic leukemia patients demonstrate that PhyloSub can infer both linear (or chain) and branching lineages and its inferences are in good agreement with ground truth, where it is available. CONCLUSIONS: PhyloSub can be applied to frequencies of any "binary" somatic mutation, including SNVs as well as small insertions and deletions. The PhyloSub and partial order plot software is available from https://github.com/morrislab/phylosub/.

Background Cancer gene expression profiling is an indispensable tool for identifying drivers of tumor progression, identifying subtypes, and predicting clinical outcome. An outstanding challenge faced by cancer gene expression studies is the limited concordance between studies [1], driven in part by lack of statistical power [2]. Part of this lack of statistical power is due to the fact that tumor samples from some solid cancers contain between 30%-70% healthy tissue [3]. This healthy tissue contaminates tumor expression profiles and variable amounts of healthy tissue leads to increased variability between tumor expression profiles. Physical purification of these tumor samples before profiling is often not feasible.